Subscribe
Home
Issues
Online First
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
Value-Based Care in Myeloma
Conference Correspondent
ASCO 2015
ASCO 2015 Highlights
CD19-Targeted 19-28z CAR-Modified T-Cells in Adult Patients with Relapsed/Refractory B-Cell ALL: Impact of MRD-Negative CR and Allogeneic Stem-Cell Transplant on Outcomes
ASH 2015 – Leukemia
,
ASH Highlights
Conference Correspondent
Read Article
Frontline Inotuzumab Ozogamicin plus Low-Intensity Chemotherapy (mini-hyper-CVD) for Older Patients with ALL
ASH 2015 – Leukemia
,
ASH Highlights
Conference Correspondent
Read Article
Dose-Intensified Pegylated-Asparaginase Pediatric Regimen in Adults with Untreated ALL: A DFCI ALL Consortium Phase 2 Trial
ASH 2015 – Leukemia
,
ASH Highlights
Conference Correspondent
Read Article
Total Therapy GIMEMA LAL 1509 Protocol for De Novo Adult Ph+ ALL Patients: Updated Results and Genetic-Based Prognostic Stratification
ASH 2015 – Leukemia
,
ASH Highlights
Conference Correspondent
Read Article
Frontline Hyper-CVAD plus Ofatumumab for Adult Patients with CD-20–Positive ALL
ASH 2015 – Leukemia
,
ASH Highlights
Conference Correspondent
Read Article
Final Results of the OPTIM Imatinib Study in Patients with CML: Personalized Daily Doses of Imatinib by Therapeutic Drug Monitoring
ASH 2015 – Leukemia
,
ASH Highlights
Conference Correspondent
Read Article
Characterization of Fever, Infection, and Cytokine Release Syndrome (CRS) in Adult Patients with Relapsed or Refractory ALL Treated with Blinatumomab
ASH 2015 – Leukemia
,
ASH Highlights
Conference Correspondent
Read Article
Single-Agent Clofarabine versus Standard Daunorubicin/Cytarabine Regimen As Induction and Consolidation Therapy in Older Adults with Newly Diagnosed AML: Results of the Phase 3 E2906 Trial
ASH 2015 – Leukemia
,
ASH Highlights
Conference Correspondent
Read Article
Clofarabine-Based Consolidation in Younger Adults with AML in First Remission: Results of the Randomized ALFA-0702/CLARA Study
ASH 2015 – Leukemia
,
ASH Highlights
Conference Correspondent
Read Article
Intermediate-Dose Cytarabine/Mitoxantrone versus Standard-Dose Cytarabine/Daunorubicin Induction Therapy in AML Patients >60 Years: Results from the SAL 60+ Trial
ASH 2015 – Leukemia
,
ASH Highlights
Conference Correspondent
Read Article
Page 176 of 329
173
174
175
176
177
178
179
Top Trending Articles
1.
ACCC Federal Policy Update Highlights Key Risks and Opportunities for Oncology Practices in 2026
Meg Barbor, MPH
2.
From Chaos to Clarity: Data-Driven Denial Prevention
Shawntea (Taya) Gordon, MBA, FACMPE
3.
The Evolving Landscape of Lung Cancer Care
Meg Barbor, MPH
Home
Issues
Online First
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
Value-Based Care in Myeloma